01:52 PM EDT, 05/15/2024 (MT Newswires) -- Takeda Pharmaceutical's ( TAK ) dengue vaccine TAK-003 received prequalification from the World Health Organization on Friday, the WHO said Wednesday.

TAK-003, a vaccine containing weakened forms of four dengue virus strains, is recommended by the WHO for children aged 6 to 16 years in high-risk areas, administered in two doses with a three-month interval.

Shares of Takeda Pharmaceutical ( TAK ) were little changed in recent Wednesday trading.

Price: 13.45, Change: +0.01, Percent Change: +0.04